Date | Title | Description | |
---|---|---|---|
24 Feb 2021 | About corporate governance | The Company informs about the agreements adopted by the Board of Directors | Download |
27 Nov 2020 | On business and financial situation | The Company publishes the results of the PRISMA-3 study of the efficacy and safety of Doria® in schizophrenic patients in the journal npj Schizophrenia | Download |
09 Jul 2020 | On business and financial situation | ROVI informs on the Collaboration with Moderna for Outside the United States Fill-Finish Manufacturing of Moderna’s COVID-19 Vaccine Candidate | Download |
Pages
Date | Title | Description | |
---|---|---|---|
10 Apr 2023 | Liquidity and counterparty agreements | Liquidity contract: transactions conducted in the first quarter of 2023 | Download |
21 Feb 2023 | Annual Report regarding remuneration of the members of the Board of Directors | ROVI releases the 2022 annual report regarding remuneration of the members of the Board of Directors | Download |
21 Feb 2023 | Annual Corporate Governance Report | ROVI releases the 2022 Annual Corporate Governance Report | Download |
16 Feb 2023 | On business and financial situation | The Company informs on the evaluation process to obtain marketing authorisation for Risvan® (Risperidone ISM®) in the United States. | Download |
09 Jan 2023 | Liquidity and counterparty agreements | Liquidity contract: transactions conducted in the fourth quarter of 2022 | Download |
Pages
Date | Title | Description | |
---|---|---|---|
24 Feb 2015 | Informe Anual de Gobierno Corporativo 2014 | Download | |
10 Feb 2015 | Otros sobre negocio y situación financiera | Download | |
16 Dec 2014 | I+D resultados obtenidos; licencias, patentes y marcas | Download | |
06 Nov 2014 | información sobre resultados | Download | |
06 Nov 2014 | información sobre resultados (2) | Download |